Capital International Ltd. CA Sells 10,433 Shares of The Cooper Companies, Inc. $COO

Capital International Ltd. CA reduced its position in The Cooper Companies, Inc. (NASDAQ:COO) by 9.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 103,691 shares of the medical device company’s stock after selling 10,433 shares during the quarter. Capital International Ltd. CA’s holdings in Cooper Companies were worth $8,499,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Capital World Investors boosted its position in shares of Cooper Companies by 25.7% in the third quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock valued at $723,417,000 after acquiring an additional 2,159,233 shares during the period. State Street Corp boosted its position in shares of Cooper Companies by 1.2% in the second quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock valued at $616,227,000 after acquiring an additional 104,910 shares during the period. Wellington Management Group LLP boosted its position in shares of Cooper Companies by 332.9% in the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after acquiring an additional 4,756,178 shares during the period. Sustainable Growth Advisers LP boosted its position in shares of Cooper Companies by 22.1% in the third quarter. Sustainable Growth Advisers LP now owns 4,132,535 shares of the medical device company’s stock valued at $283,327,000 after acquiring an additional 747,476 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Cooper Companies by 98.8% in the second quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after acquiring an additional 1,683,561 shares during the period. 24.39% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Stifel Nicolaus cut their price objective on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Friday. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research report on Friday. Robert W. Baird lowered their target price on shares of Cooper Companies from $98.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday. Piper Sandler set a $86.00 target price on shares of Cooper Companies and gave the company an “overweight” rating in a research note on Monday, June 1st. Finally, Citigroup reaffirmed a “neutral” rating and issued a $69.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $82.64.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies posted better-than-expected Q2 results, with EPS of $1.21 topping estimates of $1.10 and revenue of $1.08 billion beating forecasts, while sales rose 7.9% year over year. CooperCompanies Announces Second Quarter 2026 Results
• Positive Sentiment: Management said it reached agreements to resolve substantially all claims tied to the prior fertility media recall, reducing a major legal overhang and supporting investor confidence in the company’s outlook. QuiverQuant article
• Positive Sentiment: Needham reaffirmed a Buy rating on COO and lowered its price target to $86, still implying meaningful upside from current levels. TipRanks analyst update
• Positive Sentiment: Stifel, Baird, and JPMorgan all cut price targets but kept constructive ratings, suggesting analysts see the report as solid even after valuation resets. Benzinga analyst update
• Neutral Sentiment: The company guided FY2026 EPS to $4.58-$4.66, slightly around consensus, which helps confirm expectations but does not point to a major near-term surprise. Earnings report transcript
• Negative Sentiment: JPMorgan lowered its price target on COO from $80 to $71 and kept a Neutral rating, reflecting more cautious expectations despite the stock’s recent strength. JPMorgan price target update

Cooper Companies Trading Up 8.6%

COO stock opened at $67.34 on Friday. The company has a market capitalization of $13.14 billion, a PE ratio of 57.07, a price-to-earnings-growth ratio of 1.74 and a beta of 0.87. The Cooper Companies, Inc. has a one year low of $58.89 and a one year high of $89.83. The company’s 50 day moving average price is $65.09 and its two-hundred day moving average price is $74.52. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.79 and a current ratio of 1.34.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 EPS for the quarter, topping the consensus estimate of $1.10 by $0.11. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.85%. The business’s revenue was up 7.9% compared to the same quarter last year. During the same period last year, the firm posted $0.96 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. As a group, analysts predict that The Cooper Companies, Inc. will post 4.63 earnings per share for the current fiscal year.

Cooper Companies Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.